IBDEI0DL ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,6537,1,5,0)
 ;;=5^CAD d/t Lipid Rich Plaque
 ;;^UTILITY(U,$J,358.3,6537,2)
 ;;=^336601
 ;;^UTILITY(U,$J,358.3,6538,0)
 ;;=414.4^^55^567^16
 ;;^UTILITY(U,$J,358.3,6538,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6538,1,4,0)
 ;;=4^414.4
 ;;^UTILITY(U,$J,358.3,6538,1,5,0)
 ;;=5^CAD d/t Calc Coronary Lesion
 ;;^UTILITY(U,$J,358.3,6538,2)
 ;;=^340518
 ;;^UTILITY(U,$J,358.3,6539,0)
 ;;=425.11^^55^567^60
 ;;^UTILITY(U,$J,358.3,6539,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6539,1,4,0)
 ;;=4^425.11
 ;;^UTILITY(U,$J,358.3,6539,1,5,0)
 ;;=5^Hypertrophic Subaortic Stenosis
 ;;^UTILITY(U,$J,358.3,6539,2)
 ;;=^340520
 ;;^UTILITY(U,$J,358.3,6540,0)
 ;;=425.18^^55^567^59
 ;;^UTILITY(U,$J,358.3,6540,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6540,1,4,0)
 ;;=4^425.18
 ;;^UTILITY(U,$J,358.3,6540,1,5,0)
 ;;=5^Hypertrophic Cardiomyopathy
 ;;^UTILITY(U,$J,358.3,6540,2)
 ;;=^340521
 ;;^UTILITY(U,$J,358.3,6541,0)
 ;;=V12.55^^55^567^54
 ;;^UTILITY(U,$J,358.3,6541,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6541,1,4,0)
 ;;=4^V12.55
 ;;^UTILITY(U,$J,358.3,6541,1,5,0)
 ;;=5^Hx of Pulmonary Embolism
 ;;^UTILITY(U,$J,358.3,6541,2)
 ;;=^340615
 ;;^UTILITY(U,$J,358.3,6542,0)
 ;;=454.9^^55^567^84
 ;;^UTILITY(U,$J,358.3,6542,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6542,1,4,0)
 ;;=4^454.9
 ;;^UTILITY(U,$J,358.3,6542,1,5,0)
 ;;=5^Varicose Veins
 ;;^UTILITY(U,$J,358.3,6542,2)
 ;;=^328758
 ;;^UTILITY(U,$J,358.3,6543,0)
 ;;=271.3^^55^568^11
 ;;^UTILITY(U,$J,358.3,6543,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6543,1,4,0)
 ;;=4^271.3
 ;;^UTILITY(U,$J,358.3,6543,1,5,0)
 ;;=5^Glucose Intolerance
 ;;^UTILITY(U,$J,358.3,6543,2)
 ;;=^64790
 ;;^UTILITY(U,$J,358.3,6544,0)
 ;;=611.1^^55^568^16
 ;;^UTILITY(U,$J,358.3,6544,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6544,1,4,0)
 ;;=4^611.1
 ;;^UTILITY(U,$J,358.3,6544,1,5,0)
 ;;=5^Gynecomastia
 ;;^UTILITY(U,$J,358.3,6544,2)
 ;;=^60454
 ;;^UTILITY(U,$J,358.3,6545,0)
 ;;=704.1^^55^568^17
 ;;^UTILITY(U,$J,358.3,6545,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6545,1,4,0)
 ;;=4^704.1
 ;;^UTILITY(U,$J,358.3,6545,1,5,0)
 ;;=5^Hirsutism
 ;;^UTILITY(U,$J,358.3,6545,2)
 ;;=^57407
 ;;^UTILITY(U,$J,358.3,6546,0)
 ;;=251.2^^55^568^30
 ;;^UTILITY(U,$J,358.3,6546,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6546,1,4,0)
 ;;=4^251.2
 ;;^UTILITY(U,$J,358.3,6546,1,5,0)
 ;;=5^Hypoglycemia NOS
 ;;^UTILITY(U,$J,358.3,6546,2)
 ;;=^60580
 ;;^UTILITY(U,$J,358.3,6547,0)
 ;;=253.2^^55^568^34
 ;;^UTILITY(U,$J,358.3,6547,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6547,1,4,0)
 ;;=4^253.2
 ;;^UTILITY(U,$J,358.3,6547,1,5,0)
 ;;=5^Hypopituitarism
 ;;^UTILITY(U,$J,358.3,6547,2)
 ;;=^60686
 ;;^UTILITY(U,$J,358.3,6548,0)
 ;;=733.00^^55^568^43
 ;;^UTILITY(U,$J,358.3,6548,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6548,1,4,0)
 ;;=4^733.00
 ;;^UTILITY(U,$J,358.3,6548,1,5,0)
 ;;=5^Osteoporosis NOS
 ;;^UTILITY(U,$J,358.3,6548,2)
 ;;=^87159
 ;;^UTILITY(U,$J,358.3,6549,0)
 ;;=278.00^^55^568^40
 ;;^UTILITY(U,$J,358.3,6549,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6549,1,4,0)
 ;;=4^278.00
 ;;^UTILITY(U,$J,358.3,6549,1,5,0)
 ;;=5^Obesity
 ;;^UTILITY(U,$J,358.3,6549,2)
 ;;=^84823
 ;;^UTILITY(U,$J,358.3,6550,0)
 ;;=278.01^^55^568^39
 ;;^UTILITY(U,$J,358.3,6550,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6550,1,4,0)
 ;;=4^278.01
 ;;^UTILITY(U,$J,358.3,6550,1,5,0)
 ;;=5^Morbid Obesity
 ;;^UTILITY(U,$J,358.3,6550,2)
 ;;=^84844
 ;;^UTILITY(U,$J,358.3,6551,0)
 ;;=250.80^^55^568^10
 ;;^UTILITY(U,$J,358.3,6551,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6551,1,4,0)
 ;;=4^250.80
 ;;^UTILITY(U,$J,358.3,6551,1,5,0)
 ;;=5^DM Type II with LE Ulcer
